Interleukin-33 (IL-33) is a potent contributor to antiviral immune responses and antitumor immunity. We recently discovered that IL-33 is overexpressed in dectin-1-activated dendritic cells (DCs). However, mechanisms of dectin-1-induced IL-33 expression in DCs remain elusive. Curdlan, an agonist of dectin-1, was used to mature DCs in this study. We found that dectin-1-induced IL-33 expression in DCs relies on Syk and Raf-1 pathways. By using nuclear factor (NF)-κB inhibitors, we also found that dectin-1-induced IL-33 expression relies on NF-κB signaling. Furthermore, through Syk/Raf-1-NF-κB pathway, dectin-1 signaling stimulates DCs to overexpress interferon regulatory factor 4 (IRF4), which directly upregulates the expression of IL-33 in dectin-1-activated DCs. Thus, our study provides new insights into the mechanisms of dectin-1-induced IL-33 expression in DCs and may provide new targets for improving DC-based cancer immunotherapy.
Introduction
Dendritic cells (DCs) are professional antigen-presenting cells and play a crucial role in antitumor immunity [1, 2] . cells are shown to have better antitumor efficacy than Th1 and Th17 cells [3] [4] [5] . Cytokine milieu and DC costimulatory molecules are crucial for DCs to induce antitumor effector T cells. Therefore, strategies to stimulate DC expression of cytokines that favor the induction of antitumor effector cells may greatly increase the therapeutic efficacy of DC-based cancer immunotherapy. Interleukin-33 (IL-33) is a cytokine of the IL-1 family and the ligand for ST2 receptor [6, 7] . IL-33 is a pleiotropic cytokine that regulates the activity of both innate and adaptive immune responses. IL-33 contributes substantially in multiple inflammatory diseases, such as asthma and atopic dermatitis, by stimulating the production of type II cytokines [8] [9] [10] . IL-33 drives protective antiviral CTL responses [11] . IL-33 also acts as an immunoadjuvant and augments antigenspecific antitumor immunity [12] [13] [14] . We recently found that dectin-1-activated DCs trigger potent Th9 cell responses and antitumor immunity [15, 16] . In the mechanistic study, we identify 42 upregulated cytokines and costimulatory molecules in dectin-1-activated DCs, including IL-33 [16] . We also found that IL-33 contributes to dectin-1-activated DCinduced antitumor efficacy and Th9/1 cell differentiation (unpublished data). However, mechanisms of dectin-1-induced IL-33 expression in DCs still remain unclear.
Dectin-1 activates Syk, Raf-1 and nuclear factor (NF)-κB signaling pathways [15] [16] [17] . In this study, we found that dectin-1 enhances interferon regulatory factor 4 (IRF4) expression through Syk, Raf-1 and NF-κB pathways, which consequently increases IL-33 expression in DCs. Our study provides new insights into the mechanisms of dectin-1-induced IL-33 expression in DCs and may present new targets for improving DC-based cancer immunotherapy.
Materials and methods

Mice and reagents
C57BL/6 and Balb/c mice were purchased from the Jackson Laboratory. Dectin-1 −/− mice were provided by G. Brown (University of Aberdeen, Aberdeen, Scotland). Mice were bred and maintained in pathogen-free facilities at the First Hospital Animal Center of Jilin University. 6 to 8-week-old mice were used for the experiments. All animal experimental procedures were reviewed and approved by the Animal Ethical Committee of First Hospital of Jilin University. RPMI-1640 medium, penicillin and streptomycin were purchased from Invitrogen. Fetal bovine serum was purchased from Hyclone. Recombinant murine granulocytemacrophage colony-stimulating factor (GM-CSF), IL-4, IL-1β and tumor necrosis factor-alpha (TNF-α) were purchased from Peprotech. Recombinant human transforming growth factor-beta (TGF-β) was purchased from R&D Systems. Functional anti-mouse CD3e and CD28 antibodies (mAbs) were purchased from eBioscience. Curdlan was purchased from Sigma-Aldrich. Lipopolysaccharide (LPS) and poly I:C were purchased from Sigma-Aldrich and Invivogen respectively. Syk inhibitor Piceatannol and Raf-1 kinase inhibitor GW5074 were purchased from Calbiochem. NF-κB inhibitor Bortezomib was purchased from Selleckchem. NF-κB inhibitor (CAS 213546-53-3) was purchased from Santa Cruz, and JSH-23 (a NF-κB inhibitor) was purchased from MCE.
DC generation
Mouse immature DCs (iDCs) were generated as described previously [16, 18] . At day 7, iDCs were collected and matured in RPMI-1640 complete medium containing TNF-α (10 ng mL ) (curdlan-activated iDCs, CurDCs). At day 9, mature DCs and culture supernatants were harvested for further analysis.
In some experiments, iDCs were treated with GM-CSF (10 ng mL In some experiments, iDCs were generated from wild-type (WT) and Dectin-1 −/− C57BL/6 mice and matured with TNF-α/IL-1β or Curdlan for 2 days. In some experiments, Piceatannol (40 μM), GW5074 (1 μM), Bortezomib (10 nM), NF-κB Inhibitor (2 μg mL −1 ) or JSH-23(30 μM) was added during DC maturation, Dimethyl Sulfoxide (DMSO) (0.1%; Sigma) served as control. Cells were matured for 2 days. Mature DCs and culture supernatants were harvested for further analysis.
qPCR and western blot analyses
Quantitative PCR (qPCR) was performed as previously described [16] . Total RNA was extracted from cells by using an RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. The mRNA levels of Il33, Irf1, Irf4, Irf7 and Il9 by DCs and CD4 + T cells were analyzed. Expression was normalized to the house-keeping gene Gapdh. Primer sets used for these analyses are: IL-33: forward 5′-TTCC-AACTCCAAGATTTCCC-3′ and reverse 5′-TGTCAACAG-ACGCAGCAAA-3′; Irf1: forward 5′-GCCGAGACACTA-AGAGCAAA-3′ and reverse 5′-TGTGGTCATCAGGTA-GGGTAGA-3′; Irf4: forward 5′-AGCCCAGCAGGTTCA-TAACT-3′ and reverse 5′-CTGGCAACCATTTTCACAAG-3′; Irf7: forward 5′-CACAGCACAGGGCGTTTTA-3′ and reverse 5′-AGACAAGCACAAGCCGAGAC-3′; Il9: forward 5′-GTGTCTCTCCGTCCCAACTGATG-3′ and reverse 5′-GATTTCTGTGTGGCATTGGTCAG-3′; and Gapdh: forward 5′-TGCACCACCAA CTGCTTAGC-3′ and reverse 5′-GGATGCAGG GATGATGTTCT-3′. Western blot assay was performed as previously described [16] . Anti-mouse IRF4, β-actin antibodies and RIPA Buffer were purchased from Cell Signaling Technology (CST). Anti-mouse IRF7 was purchased from Abcam.
Enzyme-linked immunosorbent assay (ELISA)
ELISA was performed as previously described [19] . Capture and biotinylated antibodies against mouse IL-33 and recombinant mouse IL-33 standard were purchased from R&D Systems. Avidin-HRP (horseradish peroxidase) was purchased from BioLegend.
RNA interference
RNA interference was performed as previously described [16] . In brief, at day 6, iDCs were transfected with 50 nM small interfering RNA (siRNA), silencing efficacy was confirmed by qPCR. At day 8, iDCs were matured for 48 h, then mDCs were collected and analyzed by qPCR and ELISA. Syk, Raf1 and control siRNAs were shown in the previous publication [16] . siRNAs used for Irf4 are: siRNA-1 sense: 5′-GCAAGUGUUUGCUCACCAU-3′ and antisense 5′-AUG-GUGAGCAAACACUUGC-3′; siRNA-2 sense: 5′-CCAGA-CAACUGUAUUACUU-3′ and antisense 5′-AAGUAAUA-CAGUUGUCUGG-3′; siRNA-3 sense: 5′-CCGUCAUUCU-UCCAUCCAA-3′ and antisense 5′-UUGGAUGGAAGAA-UGACGG-3′. Il33 siRNAs (NM_133775) were purchased from Sigma-Aldrich.
Luciferase reporter assays
Luciferase reporter assays were performed as previously described [16] . The luciferase reporter vector pGL4.10, a control vector pGL4.74 and expression vectors for NF-κB molecules p50, p65, c-Rel, p52 and RelB were purchased from Addgene. A 2112-bp mouse Il33 promoter was cloned from mouse genomic DNA using primers: forward primer, 5′-GCTCGCTAGCCTCGAGACAGAGTGAATGAGCA-AAGAGG-3′, and reverse primer, 5′-TCTTGATAT-CCTCGAGGATTCTGCCGTGATTTCTCC-3′. The 2112-bp mouse Il33 promoter was inserted into pGL4.10 (mIl33-pGL4.10). HEK293 T cells were transiently transfected with mIl33-pGL4. 10 
Th9 cell differentiation
CurDCs with or without Il33 and Irf4 siRNAs treatment were used to generate Th9 cells as previously described [16] . After 3 days of culture, cells were harvested for the analysis of Il9 expression by qPCR.
Statistical analysis
The Student's t-test was used to compare various experimental groups. A P-value of <0.05 was considered significant.
Results
Dectin-1 stimulates IL-33 expression via Syk and Raf-1 IL-33 is overexpressed in dectin-1-activated DCs (Fig. 1a) . Syk and Raf-1 are two independent downstream signaling pathways induced by dectin-1 in DCs [17] . To investigate the role of Syk and Raf-1 signaling in dectin-1-induced IL-33 expression, Syk-specific inhibitor Piceatannol and Raf-1-specific inhibitor GW5074 were used during DC maturation. The inhibition of Syk or Raf-1 in DCs significantly decreased IL-33 expression induced by a dectin-1 agonist Curdlan (Figs. 1b, c) . In addition, by using siRNAs to specifically silence Syk or Raf1 in mouse DCs, we found that knockdown of either Syk or Raf1 in DCs reduced IL-33 expression induced by Curdlan (Figs. 1d, e) . These results showed that dectin-1-induced IL-33 expression through Syk and Raf-1 signaling pathways.
NF-κB is indirectly involved in dectin-1-induced IL-33 expression
Dectin-1 activates NF-kB via Syk and/or Raf-1 pathways [17] . To investigate the role of NF-κB signaling in dectin-1-induced IL-33 expression, Bortezomib was used during DC maturation. Bortezomib is a proteasome inhibitor, it was used to inhibit NF-κB [20] . We found that mouse DCs matured by Curdlan plus bortezomib expressed less IL-33 than cells matured by Curdlan alone (Figs. 2a, b) . To confirm the results, other two NF-κB inhibitors, NF-κB Inhibitor (CAS 213546-53-3) and JSH-23, were used. As shown in Fig. 2c , inhibiting NF-κB by either NF-κB Inhibitor or JSH-23 largely abrogated IL-33 expression in CurDCs. These results indicate that dectin-1-induced IL-33 expression through NF-κB signaling pathway.
To further determine the role of NF-κB pathway in dectin-1-induced IL-33 expression, we performed luciferase reporter assays to examine whether these NF-κB transcription factors could bind directly to Il33 promoters and activate their expression. As shown in Fig. 2d , only RelB was detected to slightly bind to and activate Il33 promoter. These results indicated that NF-κB is indirectly involved in dectin-1-induced IL-33 expression and suggested that some other factors that regulate IL-33 expression might be induced through dectin-1-triggered Syk, Raf-1 and NF-κB signaling pathways. 
Dectin-1 stimulates DCs to express IRF4
To investigate the potential transcription factors that are triggered by dectin-1 and regulate IL-33 expression, we reanalyzed the microarray gene expression data of CurDCs and BMDCs (GSE81111) [16] . We observed increased expression of IRF family member genes in CurDCs compared with BMDCs, especially Irf4 and Irf7 (Fig. 3a) . The upregulation of Irf4 mRNA, Irf7 mRNA and IRF4 protein in CurDCs compared with BMDCs was confirmed by qPCR and western blots (Figs. 3b, c) , whereas the expression of IRF7 protein remained unchanged (Fig. 3c) . Furthermore, the upregulation of IRF4 expression was completely abolished in CurDCs generated from dectin-1 −/− mice (Figs. 3c,   d ). These results showed that dectin-1 signaling enhanced IRF4 expression in DCs.
Dectin-1 signaling increases IL-33 expression via IRF4
We next investigated the role of IRF4 in dectin-1-induced expression of IL-33. Irf4-specific siRNAs were used to silence Irf4 in mouse DCs (Fig. 4a) . We found that knockdown of Irf4 in DCs inhibited IL-33 expression induced by Curdlan (Figs. 4b, c) . These results showed that dectin-1-induced IL-33 expression through the upregulation of IRF4. We previously discovered that dectin-1-activated DCs trigger potent Th9 cell response [16] . To examine the role of IRF4 and IL-33 in the induction of Th9 cells by dectin-1-activated DCs, CurDCs treated by Irf4 (si-Irf4) or Il33 (siIl33) siRNAs were used for Th9 cell induction in vitro. Th9 cells induced by si-Irf4 or si-Il33-treated CurDCs expressed lower levels of Il9 than those induced by control CurDCs (Fig. 4d) , indicating that IRF4 and IL-33 contribute dectin-1-activated DC-induced Th9 differentiation.
Dectin-1 drives IRF4 expression via Syk, Raf-1 and NF-κB pathways
To examine the role of Syk, Raf-1 and NF-κB in dectin-1-induced IRF4 expression, Syk, Raf-1 and NF-NF-κB inhibitors were used during DC maturation. The inhibition of Syk, Raf-1 or NF-κB in DCs significantly decreased + T cells under Th9-polarizing conditions. Cell cultures without (Th0) addition of Th9-polarizing cytokines TGF-β and IL-4 were used as controls. Cells were cultured for 3 days. qPCR analysis of Il9 in T cells. Data are presented as mean ± SD of three independent experiments. *P < 0.05; **P < 0.01 IRF4 expression induced by Curdlan (Figs. 5a, b) . In addition, knockdown of either Syk or Raf1 by their specific siRNAs in DCs reduced Irf4 expression induced by Curdlan (Fig. 5c) . In contrast, knockdown of Il33 in DCs does not affect IRF4 expression in CurDCs (Figs. 5d, e) . These results showed that dectin-1-induced IRF4 expression through Syk, Raf-1 and NF-κB signaling pathways.
Discussion
IL-33 is overexpressed in dectin-1-activated DCs and it plays an important role in dectin-1-activated DC-induced antitumor immunity [15, 16] . Therefore, clarifying the mechanisms of dectin-1-induced IL-33 expression may have important clinical significance. In this study, we found that dectin-1 activates Syk, Raf-1 and NF-κB downstream signaling pathways, which consequently result in increased expression of IL-33 in DCs. This result was confirmed by using Syk, Raf-1 and NF-κB inhibitors and/or siRNAs for silencing Syk or Raf-1 during DC maturation as these treatments inhibit IL-33 expression in dectin-1-activated DCs. These results are consistent with previous observations that β-glucan recognition via dectin-1 led to the induction of IL-33 [21] and NF-κB signaling is involved in IL-33 expression induced by Toll-like receptor 5 in DCs [22] . Thus, our data demonstrated Syk, Raf-1 and NF-κB as the downstream signaling pathways of dectin-1 in increasing IL-33 expression in DCs.
In this study, we found that none of NF-κB transcription factors could bind and activate the promoter of Il33 gene, suggesting that dectin-1 downstream NF-κB signaling indirectly regulates IL-33 expression. IRF transcription factors IRF3, IRF4 and IRF7 are shown to induce IL-33 expression [23] [24] [25] . We found that dectin-1 enhanced the expression of IRF1, IRF4 and IRF7, especially IRF4, suggesting that dectin-1 induces IL-33 expression via upregulation of IRF4. Indeed, knockdown of IRF4 largely abolished dectin-1-induced IL-33 expression in DCs. Furthermore, dectin-1 agonist-induced IRF4 expression relies on dectin-1 and its downstream Syk, Raf-1 and NF-κB pathways. Thus, our data identified IRF4 as the major transcription factor for dectin-1-induced IL-33 expression.
In summary, our study demonstrates that dectin-1 signaling in DCs activated Syk, Raf-1 and NF-κB pathways and enhanced the expression of IRF4, which resulted in increased expression of IL-33 (Fig. 5f) . Our study provides new insights into the mechanisms of dectin-1-induced IL-33 expression in DCs and may present new targets for improving DC-based cancer immunotherapy.
